Venetoclax combined with MEK1/2 inhibitors might therefore improve response rates in RAS-, PTPN11- and FLT3-ITD-mutated AML patients since these mutations activate the MAPK signaling pathway [83,96]. Here, PTPN11 is linked to acute myeloid leukemia.